✦ LIBER ✦

P.11.20 Results at 2years of a phase IIb extension study of the exon-skipping drug eteplirsen in patients with DMD

✍ Scribed by Mendell, J.R.; Rodino-Klapac, L.; Sahenk, Z.; Roush, K.; Bird, L.; Lowes, L.P.; Alfano, L.; Gomez, A.M.; Lewis, S.; Malik, V.; Shontz, K.; Flanigan, K.M.; Kean, J.R.; Allen, H.D.; Shilling, C.; Sazani, P.; Saoud, J.; Kaye, E.M.

Book ID: 123049165
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 61 KB
Volume: 23
Category: Article
ISSN: 0960-8966
DOI: 10.1016/j.nmd.2013.06.581

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

AOSOP6 Results from the 2-year open-labe

AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab

✍ A.T. Stopeck; A. Lipton; M. Martín; J-J. Body; A. Paterson; G.G. Steger; K. Tonk 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Adjuvant bevacizumab in patients with me

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study

✍ Corrie, Pippa G; Marshall, Andrea; Dunn, Janet A; Middleton, Mark R; Nathan, Pau 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 361 KB